Societal CDMO

Societal CDMO EBIT

Delisted

The EBIT of Societal CDMO (SCTL) as of Nov 18, 2026 is -1.76 M USD. In the previous year, EBIT was 279,000.00 USD — a change of -730.47% (lower).

EBIT

-1.76 MUSD

YoY

-730.47%

Last updated:

In 2023, Societal CDMO's EBIT was -1.76 M USD, a -730.47% increase from the 279,000.00 USD EBIT recorded in the previous year.

The Societal CDMO EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2022
279,000.00 USD
Jan 1, 2023
-1.76 M USD
Jan 1, 2024 (e)
-1.32 M USD
Jan 1, 2025 (e)
2.10 M USD
Jan 1, 2026 (e)
2.54 M USD
Jan 1, 2027 (e)
19.04 M USD
Jan 1, 2028 (e)
25.54 M USD
Jan 1, 2029 (e)
0.00 USD
The Societal CDMO EBIT history
YEAREBITYoY
est0.00USD-100.00%
est25.54 MUSD+34.17%
est19.04 MUSD+649.32%
est2.54 MUSD+20.92%
est2.10 MUSD-259.55%
est-1.32 MUSD-25.14%
-1.76 MUSD-730.47%
279,000.00USD-32.28%
412,000.00USD-104.94%
-8.34 MUSD-135.30%
23.63 MUSD-152.81%
-44.75 MUSD+11.01%
-40.31 MUSD+56.41%
-25.77 MUSD+269.77%
-6.97 MUSD-41.29%
-11.87 MUSD+989.40%
-1.09 MUSD+23.67%
-881,206.00USD-61.91%
-2.31 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Societal CDMO Revenue

Societal CDMO Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
90.21 M USD
279,000.00 USD
-19.88 M USD
Jan 1, 2023
94.64 M USD
-1.76 M USD
-13.27 M USD
Jan 1, 2024 (e)
94.65 M USD
-1.32 M USD
-8.57 M USD
Jan 1, 2025 (e)
102.30 M USD
2.10 M USD
-5.71 M USD
Jan 1, 2026 (e)
123.71 M USD
2.54 M USD
5.71 M USD
Jan 1, 2027 (e)
126.92 M USD
19.04 M USD
0.00 USD
Jan 1, 2028 (e)
145.95 M USD
25.54 M USD
0.00 USD
Jan 1, 2029 (e)
167.85 M USD
0.00 USD
0.00 USD

Societal CDMO Margins

Societal CDMO stock margins

The Societal CDMO margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Societal CDMO. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Societal CDMO.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
25.65 %
0.31 %
-22.04 %
Jan 1, 2023
19.54 %
-1.86 %
-14.03 %
Jan 1, 2024 (e)
19.54 %
-1.39 %
-9.06 %
Jan 1, 2025 (e)
19.54 %
2.05 %
-5.59 %
Jan 1, 2026 (e)
19.54 %
2.05 %
4.62 %
Jan 1, 2027 (e)
19.54 %
15.00 %
0.00 %
Jan 1, 2028 (e)
19.54 %
17.50 %
0.00 %
Jan 1, 2029 (e)
19.54 %
0.00 %
0.00 %

Societal CDMO Stock analysis

What does Societal CDMO do? Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Societal CDMO's EBIT

Societal CDMO's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Societal CDMO's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Societal CDMO's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Societal CDMO’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Societal CDMO stock

EBIT of Societal CDMO is -1.76 M USD in 2023.

EBIT of Societal CDMO changed from 279,000.00 USD to -1.76 M USD, representing a -730.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Societal CDMO since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Societal CDMO historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Societal CDMO

All Key Metrics — Societal CDMO